Screener
Haemonetics HAE Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | June 27, 2026 | March 28, 2026 |
|---|---|---|
| Building and building improvements | 109,733 | 109,793 |
| Plant equipment and machinery | 197,811 | 197,552 |
| Office equipment and information technology | 131,642 | 131,085 |
| Haemonetics equipment | 379,549 | 371,205 |
| Construction in progress | 33,216 | 29,943 |
| Property, plant and equipment, at cost | 854,272 | 841,829 |
| Less: accumulated depreciation | (550,494) | (536,068) |
| Property, plant and equipment, net | $303,778 | $305,761 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's cumulative cost basis?
- Haemonetics (HAE) reported cumulative cost basis of $854.27M in Q2 2026.
- How has Haemonetics's cumulative cost basis changed year-over-year?
- Haemonetics's cumulative cost basis increased by 7.4% year-over-year, from $795.1M to $854.27M.
- What is the long-term trend for Haemonetics's cumulative cost basis?
- Over 3 years (2023 to 2026), Haemonetics's cumulative cost basis has grown at a -3.8% compound annual growth rate (CAGR), from $944.22M to $841.83M.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about Haemonetics's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude